Right-sided tumors were more commonly associated with RAS and BRAF mutations, whereas higher EGFR expression and HER2/neu amplification were more prevalent in left-sided CRC.31, 32, 33 However, mutant KRAS was not a significant risk factor in our analysis, most likely because of incomplete available data in our cohort. The gene discussed is ERBB2; the disease is colorectal carcinoma.